MSC – Page 4 – Communicable Diseases Research

Protease Activated Receptors: A Pathway to Boosting Mesenchymal Stromal Cell Therapeutic Efficacy in Acute Respiratory Distress Syndrome?

Review

Published on 2022-01-242022-10-29
Journal: International Journal of Molecular Sciences [Category] Coronavirus,

Pulmonary Mesenchymal Stem Cells in Mild Cases of COVID-19 Are Dedicated to Proliferation; In Severe Cases, They Control Inflammation, Make Cell Dispersion, and Tissue Regeneration

Immunology

Published on 2022-01-132022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

[키워드] “cytokine storm” affected Alter Analysis biological function bronchoalveolar lavage sample CD40 Cell cell proliferation Cell therapy cell types chemotaxis clinical conditions Control COVID-19 COVID-19 patient Cytokine storm cytoplasmic Data analysis dispersion FHL2 Genes IFNGR1 IFNGR2 immune individual individuals induce inhibitor involved lung marker MDA5 mesenchymal stem cell Mild mild case mild COVID-19 patients MSC MSCs Necrosis NF-κB NFKBIA not express OPTN overexpression paracrine Patient performed PKR PPP2CB promote inflammation pulmonary receptors regeneration RNA secretion sequence Severe case severe COVID-19 single cell RNA sequencing single-cell RNA-seq STEM stem cell Target genes therapeutic therapeutic potential therapy for COVID-19 these cell tissue tlr-3 TLRs TNFR1 TNFR2 Transcription transcriptionally treat triggered upregulated upregulated gene upstream virus virus load
[DOI] 10.3389/fimmu.2021.780900 PMC 바로가기 [Article Type] Immunology

Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial

Clinical Trial

Published on 2022-01-012022-10-04
Journal: EBioMedicine [Category] 바이오마커, 임상, 치료법,

[키워드] 1-year follow-up results administration adverse event analyzed antibody benefit Biomarkers Cell China clinical trial cohort study consequence COVID-19 COVID-19 patients double-blind Effectiveness enrolled evaluate Follow-up follow-up time foundation group High-resolution CT Human in both group incidence Innovation interval Lung function lung lesion Major median mesenchymal stem cell Mesenchymal stem cells treatment MSC natural Other outcome outcomes Patient phase 2 trial Placebo placebo-controlled trial plasma positive primary endpoint Program proportion Randomized RCT RCT. recorded recruited reduced Registered reported Science severe COVID-19 stem cell Symptom technology the placebo group Treatment treatment for COVID-19 Trial tumor marker two groups UC-MSC umbilical Volume walking distance
[DOI] 10.1016/j.ebiom.2021.103789 PMC 바로가기 [Article Type] Clinical Trial

Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges

Reviews

Published on 2021-12-312022-10-30
Journal: Intensive Care Medicine Experimental [Category] COVID-19,

[키워드] acute hypoxic respiratory failure acute respiratory distress syndrome added aetiology Anti-viral therapy attenuate Cell Cell therapy Cell-based therapy cellular Clinical studies clinical study coronavirus COVID-19 pandemic Critical illness demonstrated early phase Endemic ENhance Epidemiology globe in vivo Influenza investigated Lung injury management Mesenchymal stem cells morbidity and mortality MSC MSCs outbreak pandemic Pandemics Pneumonia receiving safety profile Sepsis severe viral pneumonia supplementary material therapeutic approaches therapeutic potential therapeutic strategy therapy these cell These cells tissue translation Trial urgency viral epidemics Viral pneumonia viruses while
[DOI] 10.1186/s40635-021-00424-5 PMC 바로가기 [Article Type] Reviews

Secretome of Mesenchymal Bone Marrow Stem Cells: Is It Immunosuppressive or Proinflammatory?

Article

Published on 2021-12-012022-11-16
Journal: Bulletin of experimental biology and medicine [Category] SARS, 치료기술,

Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells

간엽 기질 세포에서 ACE2 및 TMPRRS2의 이질적 발현

Short Communication

Published on 2021-11-242022-09-10
Journal: Journal of Cellular and Molecular Medicine [Category] MERS, SARS, 진단, 치료기술, 치료제,

[키워드] ACE2 ACE2 expression ACE2 receptor adipose Adipose tissue adult stem cells binding Bone marrow Cell cell therapies cellular therapy chemokine chemokines COVID‐19 COVID‐19 infection cytokine Cytokine storm Cytokines effective enrolled expression followed by Human immune immunomodulatory factor immunomodulatory factors implicated in some Infection mesenchymal stem cell Mesenchymal stem cells mesenchymal stromal cells (MSCs) MSC MSCs multiple organ failure Organ failure outbreak potential treatment option Proinflammatory cytokine proinflammatory cytokines public health emergency SARS‐CoV‐2 SARS‐CoV‐2 secrete Severe case severe cases shown stromal cell suggested suppress target therapy tissue tissue source TMPRSS2 treat Treatment Trigger triggers umbilical Umbilical cord Vaccine virus
[DOI] 10.1111/jcmm.17048 PMC 바로가기 [Article Type] Short Communication

Treatment of COVID-19 Patients: Insights into the Use of Bone Marrow-Derived Mesenchymal Stem Cells

Conference abstract

Published on 2021-11-232022-10-05
Journal: Blood [Category] 유전자 메커니즘,

[키워드] 24 hour acute phase acute respiratory distress Administered administration administration of methylprednisolone adverse effect adverse event adverse events affected age alveolar ARDS association benefit bone Cell chronic obstructive Clinical improvement clinical trial Complete consolidation contributed Corticosteroid COVID-19 COVID-19 complications COVID-19 disease criteria CRP level death decrease defined discharged distress dose doses download drug Efficacy ferritin figure glucocorticoid High dose high mortality rate High-dose Hypothesis immunomodulatory effect include Inclusion increased risk Infection Inflammatory marker inflammatory markers insight intravenous dose intubation large cohort lung male marker median median age median time Methylprednisolone MSC observational study one patient Organizing pneumonia outcomes PaCO2 paO2/fiO2 PaO2/FiO2 ratio parameter Patient patient survival patients died patients with COVID-19 PCO2 phase primary endpoint procalcitonin pulmonary disease Pulmonary infection Randomized controlled trial reactive reducing reported respiratory parameters SARS-CoV-2 second dose secondary endpoint secure Severe COVID-19 pneumonia severity STEM stem cell suggested syndrome therapeutic option therapy Thorax tissue treat treated Treatment Trial Two patient Ventilator-associated pneumonia worsening
[DOI] 10.1182/blood-2021-154291 [Article Type] Conference abstract

Immunomodulation and Regenerative Capacity of MSCs for Long-COVID

Long-COVID에 대한 MSC의 면역 조절 및 재생 능력

Review

Published on 2021-11-172022-09-12
Journal: International Journal of Molecular Sciences [Category] MERS, SARS, 진단,

[키워드] acute lung injury acute respiratory distress acute respiratory distress syndrome ARDS Capacity clinical clinical trial clinical trials Cytokine storm death edema Effect effective drug effective drugs eventually death immunomodulation immunomodulator include Inflammation long-COVID lung lung injuries Lung injury mesenchymal stem cell Mesenchymal stem cells MSC MSCs Mutation patients with COVID-19 Post-COVID-19 patients promote provided Pulmonary edema reduce regeneration regenerative regenerative properties respiratory distress SARS-CoV-2 virus severity syndrome the disease the SARS-CoV-2 virus therapy Treatment Trial Usage
[DOI] 10.3390/ijms222212421 PMC 바로가기 [Article Type] Review

Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report

Medicine

Published on 2021-11-172022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] accelerate acute respiratory distress administration ARDS Case report CD4+ Cell cell population Cell therapy chest CT scan classical Clinical deterioration clinical trial consolidation CORD coronavirus disease COVID-19 Critically ill Critically ill patient decrease dendritic cell discharged dose Effect Efficacy fatality fibrosis Frequency ICU Ill immunomodulation increase in Inflammation inflammatory monocyte infusion intensive care intubation Invasive mechanical ventilation invasive ventilation Lung fibrosis Lung inflammation Lymphocytes male mechanical ventilation mechanically ventilated mesenchymal stromal cells (MSCs) Monocytes MSC MSC therapy PaO Patient patient with COVID-19 Peripheral blood presenting Prognosis reduced reduction reduction in report reported Serious Adverse Event severe lung inflammation stromal cell symptoms onset syndrome therapy tracheal treated vasoactive drug with COVID-19 worsening
[DOI] 10.3389/fmed.2021.767291 PMC 바로가기 [Article Type] Medicine

Stem cell-based therapy for COVID-19 and ARDS: a systematic review

Review Article

Published on 2021-11-082022-10-04
Journal: NPJ Regenerative Medicine [Category] 바이오마커, 임상,

[키워드] acute respiratory distress addition adjuvant therapy analyzed ARDS ARDS patients article Care Case series Cell Cell-based therapy clinical investigation Clinical studies clinical study clinical trials Cohort compassionate use complications concerning coronavirus disease COVID-19 Critical death effective effective intervention Efficacy eight evaluate Evidence finding FIVE global effort immunological IMPROVE Inflammatory investigated Lung injury management moderate-to-severe COVID-19 MOST MSC MSCs performed phase positive reduce mortality rate reported Respiratory tract diseases Safe severe COVID-19 standard care STEM stem cell Stem cell therapy Stem-cell research Stem-cell therapies syndrome systematic review therapy therapy for COVID-19 treat Treatment treatments for COVID-19 viral infection was performed
[DOI] 10.1038/s41536-021-00181-9 PMC 바로가기 [Article Type] Review Article